Anti-angiogenic gene therapy for metastatic renal cell carcinoma produces tumor growth suppression in an athymic nude mouse model

Journal of Urology

Volumn 179, Issue 2, 2008, Pages 737-742

  Mellon, Matthew J ^a   Ahn, Miwon ^a   Jiménez, Juan A ^a   Kao, Chinghai ^a   Gardner, Thomas A ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Adenoviridae; Carcinoma, renal cell; Gene therapy; Kidney; Mice, nude

Indexed keywords

ADENOVIRUS VECTOR; ANGIOSTATIN; BOVINE SERUM ALBUMIN; ENDOSTATIN; HYBRID PROTEIN; RHODAMINE; TYROSINE KINASE RECEPTOR; ANGIOGENESIS INHIBITOR; ANGIOSTATIC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD FLOW VELOCITY; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; EMBRYO; FLUORESCENCE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; TUMOR VASCULARIZATION; TUMOR VOLUME; XENOGRAFT; ADENOVIRUS; ANIMAL; DRUG SCREENING; GENE THERAPY; GENE VECTOR; KIDNEY TUMOR; PATHOLOGY;

ADENOVIRIDAE; ANGIOGENESIS INHIBITORS; ANGIOSTATIC PROTEINS; ANIMALS; CARCINOMA, RENAL CELL; GENE THERAPY; GENETIC VECTORS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 38849147224     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.09.017     Document Type: Article

References (20)

1. Pantuck AJ, Zisman A and Belldegrun AS: The changing natural history of renal cell carcinoma. J Urol 2001;166:1611.
2. Chow WH, Devesa SS, Warren JL and Fraumeni JF Jr: Rising incidence of renal cell cancer in the United States. JAMA 1999;281:1628.
3. Motzer RJ, Bacik J and Mazumdar M: Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering cancer center experience. Clin Cancer Res 2004;10:6302S.
4. Muss HB: Interferon therapy for renal cell carcinoma. Semin Oncol 1987;14:36.
5. Patel PH, Chaganti RS and Motzer RJ: Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006;94:614.
6. Dumont DJ, Gradwohl GJ, Fong GH, Auerbach R and Breitman ML: The endothelial-specific receptor tyrosine kinase, tek, is a member of a new subfamily of receptors. Oncogene 1993;8:1293.
7. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277.
8. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Cao Y et al: Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol 1994;59:471.
9. Feldman AL, Restifo NP, Alexander HR, Bartlett DL, Hwu P, Seth P et al: Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res 2000;60:1503.
10. Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R et al: Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A 2001;98:4605.
11. Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD et al: Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci U S A 1998;95:8829.
12. Raikwar SP, Temm CJ, Raikwar NS, Kao C, Molitoris BA and Gardner TA: Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model. Mol Ther 2005;12:1091.
13. Ebert T, Bander NH, Finstad CL, Ramsawak RD and Old LJ: Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res 1990;50:5531.
14. Calvo A, Feldman AL, Libutti SK and Green JE: Adenovirusmediated endostatin delivery results in inhibition of mammary gland tumor growth in C3 (1)/SV40 T-antigen transgenic mice. Cancer Res 2002;62:3934.
15. Scappaticci FA, Smith R, Pathak A, Schloss D, Lum B, Cao Y et al: Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol Ther 2001;3:186.
16. Wood M, Perrotte P, Onishi E, Harper ME, Dinney C, Pagliaro L et al: Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther 1999;6:367.
17. Folkman J: Antiangiogenic gene therapy. Proc Natl Acad Sci U S A 1998;95:9064.
18. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA et al: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998;394:287.
19. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J et al: The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61:3369.
20. Zhang Q, Nie M, Sham J, Su C, Xue H, Chua D et al: Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene. Cancer Res 2004;64:5390.